Biocubafarma, ten years later. Challenges and projections

Authors

  • Eduardo Martínez Díaz Presidente de BioCubaFarma. Académico Titular, Academia de Ciencias de Cuba. La Habana.
  • Mayda Mauri Pérez Vice-Presidenta Primera de BioCubaFarma. La Habana.
  • Tania Urquiza Rodríguez Vice-Presidenta de BioCubaFarma. La Habana.
  • Eulogio Pimentel Vázquez Vice-Presidente de BioCubaFarma. La Habana.
  • Rita María García Almaguer Directora de Operaciones de BioCubaFarma. La Habana.
  • David Curbelo Rodríguez Director Comercial y de Negocios de BioCubaFarma. La Habana.
  • Rolando Pérez Rodríguez Director de Ciencia e Innovación de BioCubaFarma. Académico de Mérito, Academia de Ciencias de Cuba. La Habana.
  • Santiago Dueñas Carrera Director de Inversiones de BioCubaFarma. La Habana.
  • Pablo Fonseca Rodríguez Director de Economía de BioCubaFarma. La Habana.
  • Judith Sartorio Enríquez Directora de Calidad y Asuntos Regulatorios de BioCubaFarma. La Habana.
  • Rodolfo A. Parra Rojas Director de Capital Humano de BioCubaFarma. La Habana.
  • Georgina Flavia González Martínez Directora de Logística de BioCubaFarma. La Habana.
  • Bárbara Milagros González Carnel Directora de Cuadros de BioCubaFarma. La Habana.
  • Ismary Núñez Broño Directora de Información y Comunicación de BioCubaFarma. La Habana.

Keywords:

biotecnología cubana, industria farmacéutica cubana, ciencia cubana

Abstract

Cuba has extensive experience in the development of the biotechnology and pharmaceutical industries, created by Commander in Chief Fidel Castro Ruz, leader of the Cuban Revolution. The historical progress of this sector is marked by several milestones, starting with the creation of the National Center for Scientific Research in 1965, the constitution of the Biological Front in 1981, that turned into the Scientific Pole of Western Havana in 1992, the constitution of QUIMEFA in 2001 and the creation of the BioCubaFarma Business Group, in 2012.

Throughout these years, important results have been achieved for the health of the Cuban people. Currently, the biopharmaceutical industry is consolidating itself as an emerging sector of the knowledge economy in our country. The international scientific community recognizes the progress made by Cuba in this sector, which has had its maximum expression in the confrontation to the COVID-19 pandemic, especially in the development of safe and effective vaccines against this disease.

Downloads

Download data is not yet available.

Downloads

Published

2024-01-14

How to Cite

Martínez Díaz, E., Mauri Pérez, M., Urquiza Rodríguez, T., Pimentel Vázquez, E., García Almaguer, R. M., Curbelo Rodríguez, D., … Núñez Broño, I. (2024). Biocubafarma, ten years later. Challenges and projections. Anales De La Academia De Ciencias De Cuba, 14(1), e1529. Retrieved from https://revistaccuba.sld.cu/index.php/revacc/article/view/1529

Issue

Vol. 14 No. 1: January-March 2024

Section

Contribuciones especiales

License

The journal Anales de la Academia de Ciencias de Cuba protects copyright, and operates with a Creative Commons License 4.0 (Creative Commons Attribution-NonCommercial License 4.0). By publishing in it, authors allow themselves to copy, reproduce, distribute, publicly communicate their work and generate derivative works, as long as the original author is cited and acknowledged. They do not allow, however, the use of the original work for commercial or lucrative purposes.

The authors authorize the publication of their writings, retaining the authorship rights, and assigning and transferring to the magazine all the rights protected by the intellectual property laws that govern in Cuba, which imply editing to disseminate the work.

Authors may establish additional agreements for the non-exclusive distribution of the version of the work published in the journal (for example, placing it in an institutional repository or publishing it in a book), with recognition of having been first published in this journal.

To learn more, see https://creativecommons.org